Introduction:
Vidac Pharma Holding plc, a London-based pharmaceutical company, has reported promising preclinical results for its cancer drug candidate VDA-1275. The small molecule showed efficacy as a monotherapy and synergistic effects in combination with other cancer treatments. It also induced an immunologic response, including the production of anti-cancer memory T-cells. VDA-1275 disrupts the interaction between hexokinase 2 and voltage-dependent anion channels in mitochondria, which is necessary for tumor growth.
- VDA-1275 showed statistically significant efficacy as a monotherapy in a murine colorectal cancer model, with similar survival benefit to a cancer immunotherapy drug.
- VDA-1275 also showed statistically significant survival benefits in human and murine cell culture models of lung, prostate, and colon cancer.
- In a 3D organoid model of human liver cancer, VDA-1275 reduced the concentrations of two standard-of-care cancer drugs needed to achieve cancer cell viability.
- VDA-1275 induced an immune response by promoting the production of anti-tumor M1 macrophages and shifting CD8+ T-cells to memory cells.
- The company plans to publish the results of its preclinical studies.
Conclusion:
The preclinical results suggest that VDA-1275 has potential as a cancer treatment, both as a monotherapy and in combination with other drugs. It has shown efficacy in multiple cancer types and has the ability to induce an immune response. Further research is needed to validate these findings and explore the potential of VDA-1275 in clinical settings.
